Document Detail

Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
MedLine Citation:
PMID:  21487213     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND AIMS: There has been limited study of estrogen and progesterone receptor (ER/PR) expression in gastrointestinal neuroendocrine tumors (GINETs) despite emerging evidence of hormone receptor regulation of pancreatic islet cells. Beta cells express PR and progesterone has been implicated in the pathogenesis of gestational diabetes. There is conflicting information regarding HER2/neu protein overexpression in GINETs. Investigation of ER, PR and HER2/neu expression in GINETs is therefore warranted.
METHODS: A pathology database search identified 77 patients with primary pancreatic (40) or small intestinal (37) NETs diagnosed from 1991 to 2009. Ki67, ER, PR and HER2/neu were assessed via immunohistochemistry. ER and PR were interpreted as negative (0), 1+ (Allred score 3-7/8) or 2+ (Allred score 8/8), and HER2/neu was assessed according to ASCO/CAP guidelines for breast carcinoma. Clinical correlation and survival outcomes were ascertained by a retrospective clinical chart review.
RESULTS: 2+ PR staining was observed more often in pancreatic compared to small intestinal cases (55 vs. 8%; p < 0.001). All small intestinal NETs with 2+ PR were duodenal primaries. Cases with 2+ PR presented significantly less often with nodal or distant metastases compared to cases with 0/1+ PR (13 vs. 61.5%; p < 0.001) and had significantly improved disease-free survival (median 155 vs. 38 months; p = 0.037). Only one case demonstrated 2+ ER staining and all were negative for HER2/neu.
CONCLUSION: GINETs with strong (2+) PR expression are associated with pancreatic/duodenal origin, lower stage disease, and more favorable clinical prognosis. Further study is needed to determine the clinical utility of PR expression in GINETs.
Thomas Arnason; Heidi L Sapp; Penelope J Barnes; Magdalena Drewniak; Mohamed Abdolell; Daniel Rayson
Related Documents :
21330923 - Update on targeted therapies for clear cell renal cell carcinoma.
17902123 - Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outc...
7853583 - A new approach using local combined microwave hyperthermia and chemotherapy in superfic...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-04-10
Journal Detail:
Title:  Neuroendocrinology     Volume:  93     ISSN:  1423-0194     ISO Abbreviation:  Neuroendocrinology     Publication Date:  2011  
Date Detail:
Created Date:  2011-06-21     Completed Date:  2011-10-13     Revised Date:  2012-10-12    
Medline Journal Info:
Nlm Unique ID:  0035665     Medline TA:  Neuroendocrinology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  249-58     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Division of Anatomical Pathology, Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, N.S., Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Duodenal Neoplasms / metabolism*,  mortality,  pathology
Kaplan-Meier Estimate
Middle Aged
Neuroendocrine Tumors / metabolism*,  mortality,  pathology
Pancreatic Neoplasms / metabolism*,  mortality,  pathology
Receptor, erbB-2 / metabolism*
Receptors, Estrogen / metabolism*
Receptors, Progesterone / metabolism*
Retrospective Studies
Tumor Markers, Biological / metabolism
Young Adult
Reg. No./Substance:
0/Receptors, Estrogen; 0/Receptors, Progesterone; 0/Tumor Markers, Biological; EC protein, human; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prolyl Endopeptidase Is Involved in Cellular Signalling in Human Neuroblastoma SH-SY5Y Cells.
Next Document:  Introduction of Potentially Allergenic Foods in the Infant's Diet during the First Year of Life in F...